HENGRUI PHARMA (01276.HK) -1.050 (-1.683%) Short selling $39.38M; Ratio 19.628% closed at HKD67.7 in the morning session today (12th), up 2.5%. The company announced at noon that it had reached global strategic collaboration and license agreements with Bristol-Myers Squibb Company (BMS)(BMY.US) , which would bring in USD950 million in related payments. The share price rallied in the afternoon, last trading at HKD75, up 13.55%, with 5.6465 million shares traded, amounting to HKD394 million. HENGRUI PHARMA (600276.SH) -0.980 (-1.905%) A-shares last soared 5.6% at RMB56.49.Related News G Sachs: Continue to Favor Visibility-led CDMO, Closely Watch Early Signs of Market BottomingHENGRUI PHARMA announced that it had entered into global strategic collaboration and license agreements with BMS to advance a portfolio of 13 early stage programs in oncology, hematology and immunology. Under the agreement, BMS will pay HENGRUI PHARMA up to USD950 million, including a USD600 million upfront payment, a USD175 million first anniversary payment, and a second contingent anniversary payment of USD175 million in 2028. The potential total value of the agreements is up to approximately USD15.2 billion, including the exercise of available options for the joint discovery programs and the achievement of applicable development, regulatory, and commercial milestones for all programs. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.) (A Shares quote is delayed for at least 15 mins.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)
AASTOCKS Financial News